drugset / Trial / NCT05057767

Impact of Timing of Midazolam Administration on Incidence of Postoperative Nausea and Vomiting

NCT05057767

Completed 120 enrolled Benha University
RandomizedParallel-groupDouble-blindPrevention

Summary

Postoperative nausea and vomiting (PONV), defined as nausea and/or vomiting occurring within 24 hours after surgery, affects between 20% and 30% of patients, As many as 70% to 80% of patients at high risk may be affected. The etiology of PONV is thought to be multifactorial, involving individual, anaesthetic and surgical risk factors. PONV results in increased patient discomfort and dissatisfaction and in increased costs related to length of hospital stay. Serious medical complications such as pulmonary aspiration, although uncommon, are also associated with vomiting. Patients with a higher risk of PONV often require a combination or multimodal approach of 2 or more interventions for effective risk reduction. Thus, researchers have explored additional nontraditional antiemetics, such as midazolam, that would aid in the multimodal prevention of PONV.

Timeline

Start
2021-09-10
Primary completion
2022-06-30
Completion
2022-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Midazolam Small molecule 2 mg Intravenous

Indications

No indication recorded.